Insider Trading March 31, 2026

RENN Fund President Murray Stahl Buys $3,666 in RCG Shares

Multiple affiliated accounts acquire 1,128 shares at $3.25 as RENN Fund trades near its 52-week high

By Marcus Reed RCG
RENN Fund President Murray Stahl Buys $3,666 in RCG Shares
RCG

Murray Stahl, president and co-portfolio manager of RENN Fund, Inc. (RCG), reported purchases totaling 1,128 shares executed on March 30, 2026, at $3.25 per share. The combined outlay was $3,666. After the transactions, Stahl holds 158,888 shares directly and additional indirect holdings through various entities, which he disclaims beneficial ownership of except to the extent of his pecuniary interest. RCG is trading near its 52-week high and the fund has a market capitalization of $22.9 million and a six-month return of 26.5%.

Key Points

  • Stahl executed purchases totaling 1,128 RCG shares at $3.25 per share on March 30, 2026, for a combined investment of $3,666 - impacting the financials and asset management sectors.
  • After the transactions, Stahl directly holds 158,888 shares and also has indirect holdings via several affiliated entities, with a formal disclaimer of beneficial ownership for those indirect stakes - relevant to corporate governance and ownership disclosure practices.
  • RCG was trading at $3.27, close to its 52-week high of $3.31; the fund has a $22.9 million market capitalization and a six-month return of 26.5% - points of interest for investors and market participants monitoring fund performance.

Summary

Murray Stahl, who serves as president and co-portfolio manager of RENN Fund, Inc. (RCG), reported a series of purchases of the fund's common stock on March 30, 2026. The transactions added up to 1,128 shares bought at $3.25 apiece, for a total cash outlay of $3,666.

Transaction details

The reported trades were executed at a uniform price of $3.25 per share. Stahl acquired the shares through a mix of direct and affiliated accounts, including transactions conducted in his spouse's name, Fromex Equity Corp., FRMO Corp., Horizon Common Inc., Horizon Kinetics Hard Assets LLC, and Horizon Kinetics Asset Management LLC, as well as purchases made directly by Stahl.

Post-transaction holdings and ownership statement

Following these buys, Stahl directly owns 158,888 shares of RENN Fund, Inc. He also has additional holdings that are held indirectly through the entities noted above. In public filings, he disclaims beneficial ownership of those indirectly held shares except to the extent of his pecuniary interest.

Market context provided in the filing

At the time of the report, RCG was trading at $3.27, a level noted to be close to the stock's 52-week high of $3.31, according to InvestingPro data referenced in the filing. The fund's market capitalization is reported as $22.9 million. Over the most recent six-month period cited in the filing, RENN Fund returned 26.5%.

Additional notes

The filing lists the precise dollar amount of the purchase activity and details the accounts involved. The disclosure of indirect holdings and the disclaimer of beneficial ownership for those indirect positions are part of the record accompanying the reported trades.


Key points and considerations appear below in a concise format for clarity.

Risks

  • The purchase size is modest - $3,666 against a $22.9 million market capitalization - which may limit the transaction's market impact and signal ambiguity about broader insider conviction.
  • Stahl disclaims beneficial ownership of shares held indirectly except to the extent of his pecuniary interest, introducing complexity into the precise measurement of his effective economic exposure.
  • The stock's trade near its 52-week high indicates current price positioning that investors may view as an uncertainty in assessing near-term valuation and performance.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026